Axis Direct
Considering overall stellar performance we have incresed earnings for FY22E & FY23E and increased target price to INR 1,670 with Buy recommendations.
Promoters pledged 5.53% of shares in last quarter. Total pledge stands at 31.57% of promoter holdings
More from Solara Active Pharma Sciences Ltd.
Recommended